Navigation Links
Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
Date:5/16/2012

ND with R256.

ATS Poster Presentations
A Randomized, Placebo Controlled Trial of the Effect of an Inhaled SYK Inhibitor on Allergen Induced Airways Responses in Mild Asthma (R343)
May 21, 2012, 8:15AM – 4:30PM
Poster Session: B33 – ASTHMA THERAPY: NOVEL APPROACHES

Janus Kinase (JAK) 3 Inhibitor, R256, Attenuates Allergen-Induced Airway Hyperresponsiveness and Airway Inflammation in Mice
May 21, 2012, 8:15AM – 4:30PM
Poster Session: B33 – ASTHMA THERAPY: NOVEL APPROACHES

R256 Is a Potent and Selective IL13/4 Receptor Signaling Inhibitor That Reduces Inflammation In a Mouse Model of Chronic Asthma
May 21, 2012, 8:15AM – 4:30PM
Poster Session: B37 – NEW INSIGHTS INTO ASTHMA AND COPD TREATMENT

About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral SYK inhibitor that is in Phase 3 clinical trials for rheumatoid arthritis with our partner AstraZeneca; R343, an inhaled SYK inhibitor that has completed Phase 1 clinical trials for asthma; R333, a topical JAK/SYK inhibitor for discoid lupus; and R548, an oral JAK3 inhibitor for the treatment of transplant rejection and other immune disorders.

This press release contains "forward-looking" statements, including, without limitation, statements related to Rigel's future product candidate pipeline and strategy.  Any statements contained in this pres
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
2. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
3. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
4. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
5. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
6. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
7. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
8. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
9. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
10. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
11. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... ANDOVER, Mass. , Aug. 30, 2014   ... launch of Affiniti, a new ultrasound system ... overcome the demands of increasing patient volumes and cost ... Cardiology (ESC) Congress 2014 in Barcelona ... radiology/ultrasound departments facing more patients with fewer resources deliver ...
(Date:8/29/2014)... DALLAS , Aug. 29, 2014 /PRNewswire-iReach/ -- ... Crystallography Scanner Industry, 2009-2019 is a professional and ... X-Ray Crystallography Scanner industry . The report firstly ... including its classification, application and manufacturing technology. The ... of X-Ray Crystallography Scanner listing their product specification, ...
(Date:8/29/2014)... ANGELES , Aug. 29, 2014  Chuma ... both financing alternatives and turnkey support services for ... announce that FINRA processed and approved the Company,s ... 29, 2014, CannaMed Corporation will be known as ... change was accomplished through a merger with the ...
Breaking Medicine Technology:Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3
... 16, 2011  Kensey Nash Corporation (NASDAQ: KNSY ) ... to enter into non-binding mediation in an attempt to resolve ... Angio-Seal vascular closure device, as well as other related claims. ... are currently to be paid, and should since 2007 have ...
...  Pharmasset, Inc. (Nasdaq: VRUS ) announced today ... QUANTUM Phase 2b trial of the guanine nucleotide analog ... containing PSI-938. There are 235 individuals with hepatitis C ... with PSI-938 alone or in combination with PSI-7977 or ...
Cached Medicine Technology:Kensey Nash to Enter Into Mediation with St. Jude Medical over Angio-Seal Contract Disputes 2Kensey Nash to Enter Into Mediation with St. Jude Medical over Angio-Seal Contract Disputes 3Kensey Nash to Enter Into Mediation with St. Jude Medical over Angio-Seal Contract Disputes 4Pharmasset Announces Intent to Amend QUANTUM Trial 2Pharmasset Announces Intent to Amend QUANTUM Trial 3
(Date:8/30/2014)... 30, 2014 In today’s world, a good ... get. Snoring and sleep apnea (a medical problem where the ... their bed partners of the rest they need to face ... population snores and 20 million people in the United States ... diagnosed and treated; and of those treated, many cannot tolerate ...
(Date:8/30/2014)... 30, 2014 Market Research Report ... is a professional and in-depth market survey on ... firstly reviews the basic information of Lab Oven ... report then explores global and China’s top manufacturers ... production value, and market share etc. , The ...
(Date:8/30/2014)... New York (PRWEB) August 30, 2014 ... for transvaginal mesh lawsuits ( http://www.injurybeacon.com/transvaginal-mesh/ ) filed ... request to sever four cases selected for one ... Order issued on August 18, 2014, U.S. District ... of West Virginia disagrees with Boston Scientific’s contention ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 In today’s ... and increasingly difficult to get. Snoring and sleep apnea ... and breathing stops) robs people and their bed partners ... challenges. Up to 45% of the population snores and ... sleep apnea. Of these, only 10% have been diagnosed ...
(Date:8/30/2014)... Delhi, India (PRWEB) August 30, 2014 ... online reputation management industry, has announced to offer guarantee ... has decided to offer this guarantee because of its ... more than 200 clients from all over the world ... doing extremely good job. , On being asked ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Removecomplaints.net Announces Guaranteed Complaints Removal Services 2
... in two men and one in three women, cancer remains ... This year, in the nation,s capital, the American Association for ... draw more than 17,000 academics, scientists, clinicians, industry leaders, survivors ... findings in this fast-moving arena. To help you ...
... Remedi ... Ohio long-term care marketplace. , ... Baltimore, Md. (PRWEB) February 4, 2010 -- Remedi SeniorCare has expanded its ... new customers for its comprehensive pharmacy services., , ,Vista Grande Villa of Jackson, Michigan, ...
... 50 ... “text to” donation number on February 6th to heighten awareness about the Haitian crisis ... ... nonprofit dedicated to providing health care services to underprivileged children in resource limited countries, ...
... to preventive treatment, researchers say , THURSDAY, Feb. 4 ... in mothers and fetuses that appear to boost the ... traits are found in genes that regulate inflammation -- ... material that holds cells within tissues. , "A ...
... ... a perfect one of a kind Valentines gift. , ... Naperville, IL (PRWEB) February 4, 2010 -- The concept of ... couples to spend wonderful time away from distractions while enjoying fellowship with other couples and ...
... , As Lower-Cost Methadone Prescribing Increases, ... Feb. 4 In a unique and ... -- 2009, the deaths involving methadone were found to be ... opioid prescriptions but is responsible for a third of the ...
Cached Medicine News:Health News:Two Long-Term Care Organizations Select Remedi SeniorCare for Pharmacy Services 2Health News:Two Long-Term Care Organizations Select Remedi SeniorCare for Pharmacy Services 3Health News:One5 Foundation Launches National Haitian Relief Campaign with TShirtAds 2Health News:One5 Foundation Launches National Haitian Relief Campaign with TShirtAds 3Health News:The Love Convention Returns With "Something New" at Hotel Arista on Valentines Weekend 2Health News:The Love Convention Returns With "Something New" at Hotel Arista on Valentines Weekend 3Health News:Methadone and Other Opioids Not Always Equivalent, Conversion Can Be Lethal 2Health News:Methadone and Other Opioids Not Always Equivalent, Conversion Can Be Lethal 3Health News:Methadone and Other Opioids Not Always Equivalent, Conversion Can Be Lethal 4
Console Horizontal Airflow Cabinet...
... Ideal for biocompatibility testing at various ... of air through a clean heating ... temperature up to 140F. Transparent panels ... shields allow easy access to the ...
Ideal for chemical processing that requires downward flow of exhaust fumes. Powderful 1200 CFM blower draws fumes into sub-surface bonded charcoal filter for safe removal of organic vapors (final HEP...
This modular benchtop fume hood ventilates and purifies chemical fumes, allowing safe indoor release of exhaust. Bonded charcoal filters remove most organic contaminants. Options include final HEPA f...
Medicine Products: